Table 3.
Population-level burden: incremental costs associated with poor glycemic control and failure to intensify therapy (baseline HbA1c of 9.0% [75 mol/mol], target HbA1c of 7.0% [53 mmol/mol])
| Intensification delay, years | Time horizon, years | |||||
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 5 | 10 | 30 | |
| Reduction in life expectancy with poor glycemic control, years | ||||||
| 1 | 13,390 | 26,779 | 53,558 | 80,337 | 214,233 | 642,699 |
| 2 | – | 26,779 | 53,558 | 93,727 | 361,518 | 1,178,282 |
| 3 | – | – | 66,948 | 133,896 | 388,298 | 1,727,255 |
| 5 | – | – | – | 147,285 | 535,583 | 2,383,343 |
| 7 | – | – | – | – | 642,699 | 2,999,264 |
| Cost of diabetes-related complications, USD millions | ||||||
| 1 | 1755 | 3013 | 3848 | 5182 | 9707 | 16,637 |
| 2 | – | 4094 | 5815 | 8508 | 16,233 | 31,260 |
| 3 | – | – | 6791 | 11,540 | 21,748 | 42,659 |
| 5 | – | – | – | 14,285 | 31,061 | 65,413 |
| 7 | – | – | – | – | 37,248 | 82,639 |
| Lost productivity costs, USD millions | ||||||
| 1 | 5551 | 9088 | 11,795 | 16,494 | 31,181 | 34,554 |
| 2 | – | 13,048 | 18,327 | 27,246 | 53,879 | 61,339 |
| 3 | – | – | 22,417 | 36,682 | 68,709 | 83,596 |
| 5 | – | – | – | 45,889 | 97,257 | 114,227 |
| 7 | – | – | – | – | 115,701 | 140,688 |
| Total costs, USD millions | ||||||
| 1 | 7306 | 12,101 | 15,642 | 21,676 | 40,888 | 51,192 |
| 2 | – | 17,142 | 24,143 | 35,754 | 70,112 | 92,599 |
| 3 | – | – | 29,208 | 48,222 | 90,457 | 126,255 |
| 5 | – | – | – | 60,174 | 128,318 | 179,640 |
| 7 | – | – | – | – | 152,949 | 223,326 |
HbA1c glycated hemoglobin, USD United States dollars